CN115867557A - 氮杂卓类稠环化合物及其医药用途 - Google Patents

氮杂卓类稠环化合物及其医药用途 Download PDF

Info

Publication number
CN115867557A
CN115867557A CN202280005442.8A CN202280005442A CN115867557A CN 115867557 A CN115867557 A CN 115867557A CN 202280005442 A CN202280005442 A CN 202280005442A CN 115867557 A CN115867557 A CN 115867557A
Authority
CN
China
Prior art keywords
cycloalkyl
alkyl
heterocyclyl
heteroaryl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280005442.8A
Other languages
English (en)
Inventor
闫旭
刘国标
王国政
沙汉明
李斌
李建浩
辛丕明
刘延鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Pharmaceutical R&D Co Ltd
Original Assignee
National Institutes of Pharmaceutical R&D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Pharmaceutical R&D Co Ltd filed Critical National Institutes of Pharmaceutical R&D Co Ltd
Publication of CN115867557A publication Critical patent/CN115867557A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

一种氮杂卓类稠环化合物及其医药用途。具体地，涉及通式(I)所示的氮杂卓类稠环化合物，其制备方法，含有其的药物组合物，以及其作为受体相互作用蛋白激酶1(RIP1)抑制剂，用于治疗与RIP1活性相关的疾病的用途。其中通式(I)中的各取代基的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202280005442.8A 2021-05-14 2022-05-13 氮杂卓类稠环化合物及其医药用途 Pending CN115867557A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110526950 2021-05-14
CN2021105269508 2021-05-14
PCT/CN2022/092607 WO2022237890A1 (zh) 2021-05-14 2022-05-13 氮杂卓类稠环化合物及其医药用途

Publications (1)

Publication Number Publication Date
CN115867557A true CN115867557A (zh) 2023-03-28

Family

ID=84028185

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280005442.8A Pending CN115867557A (zh) 2021-05-14 2022-05-13 氮杂卓类稠环化合物及其医药用途

Country Status (3)

Country Link
CN (1) CN115867557A (zh)
TW (1) TW202311261A (zh)
WO (1) WO2022237890A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115038707A (zh) * 2020-05-14 2022-09-09 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108431004A (zh) * 2015-10-23 2018-08-21 武田药品工业株式会社 杂环化合物
CN109134448A (zh) * 2018-10-16 2019-01-04 中南大学湘雅医院 杂环化合物及其盐、制备方法、用途和药物
CN110642874A (zh) * 2018-06-26 2020-01-03 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途
CN112384510A (zh) * 2018-05-03 2021-02-19 里格尔药品股份有限公司 Rip1抑制性化合物以及制备和使用其的方法
WO2021046437A1 (en) * 2019-09-06 2021-03-11 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
CN115038707A (zh) * 2020-05-14 2022-09-09 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112079839A (zh) * 2019-06-15 2020-12-15 察略盛医药科技(上海)有限公司 内酰胺类衍生物、其制备方法及其在医药上的用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108431004A (zh) * 2015-10-23 2018-08-21 武田药品工业株式会社 杂环化合物
CN112384510A (zh) * 2018-05-03 2021-02-19 里格尔药品股份有限公司 Rip1抑制性化合物以及制备和使用其的方法
CN110642874A (zh) * 2018-06-26 2020-01-03 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途
CN109134448A (zh) * 2018-10-16 2019-01-04 中南大学湘雅医院 杂环化合物及其盐、制备方法、用途和药物
WO2021046437A1 (en) * 2019-09-06 2021-03-11 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
CN115038707A (zh) * 2020-05-14 2022-09-09 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASATO YOSHIKAWA 等: "Discovery of 7-Oxo-2, 4, 5, 7-tetrahydro-6H-pyrazolo[3, 4-c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships", 《J.MED.CHEM.》, vol. 61, no. 6, 27 February 2018 (2018-02-27), pages 2384 - 2409, XP055594700, DOI: 10.1021/acs.jmedchem.7b01647 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115038707A (zh) * 2020-05-14 2022-09-09 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途

Also Published As

Publication number Publication date
WO2022237890A1 (zh) 2022-11-17
TW202311261A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
CN109983007B (zh) 酰胺类衍生物抑制剂及其制备方法和应用
CN111295384B (zh) 双环类衍生物抑制剂、其制备方法和应用
TWI664175B (zh) 用於作為shp2抑制劑之新穎雜環衍生物
CN110627796B (zh) 含氮杂环类衍生物及其在医药上的应用
WO2020108590A1 (zh) 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN112368283B (zh) 含二并环类衍生物抑制剂、其制备方法和应用
CN111107848B (zh) 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
CN113637005A (zh) 用于癌症治疗的kras抑制剂
TW202214605A (zh) 免疫調節劑、組合物及其方法
AU2022218560B2 (en) Benzoazepine analogs as inhibiting agents for Bruton's tyrosine kinase
BR112016011024B1 (pt) Composto, composição farmacêutica, e, usos dos mesmos
JP2018514537A (ja) イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
CN106432246B (zh) 杂芳化合物及其在药物中的应用
CN106336413B (zh) 作为jak抑制剂的化合物及其用途
CN115038707A (zh) 氮杂卓类稠环化合物及其医药用途
CN113072551A (zh) 含氮联苯类衍生物抑制剂、其制备方法和应用
TW202102511A (zh) 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用
CN115867557A (zh) 氮杂卓类稠环化合物及其医药用途
CN111320633A (zh) 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
CN111320624A (zh) 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
CN112654605B (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
CN116969971A (zh) 含氮大环类化合物及其制备方法和医药用途
CN115141202A (zh) 嘧啶并吡嗪酮化合物及其用途
WO2022002243A1 (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CN105461709B (zh) 取代脲衍生物及其在药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082452

Country of ref document: HK